Replies to post #12282 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Copaxone's volume are dropping way more than anyone here expected…

Not true; according to Teva’s 2Q14 CC slides, the reduction in US Copaxone sales from 1Q14 to 2Q14 was due to inventory destocking, not lack of demand. See http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjQ1MjMzfENoaWxkSUQ9LTF8VHlwZT0z&t=1 slide #11.